Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Study Identifier:
ALXN1210-MG-306
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
- Drug: Placebo
Date
Mar 2019 - May 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
- Drug: Placebo
Date
Mar 2019 - May 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
Trial Locations
Location
Status
Location
Research Site
Phoenix, Arizona, United States, 85013
Status
N/A
Location
Research Site
Phoenix, Arizona, United States, 85018
Status
N/A
Location
Research Site
Phoenix, Arizona, United States, 85028
Status
N/A
Location
Research Site
Irvine, California, United States, 92617
Status
N/A
Location
Research Site
Loma Linda, California, United States, 92354
Status
N/A
Location
Research Site
Palo Alto, California, United States, 94304
Status
N/A